UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

 FORM 8-K

 CURRENT REPORT

 Pursuant to Section 13 or 15(d)

 of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): May 13, 2025

 NUCOR CORPORATION

 (Exact name of Registrant as Specified in Its Charter)

 Delaware

 1-4119

 13-1860817

 (State or Other Jurisdiction

 of Incorporation)

 (Commission

 File Number)

 (IRS Employer

 Identification No.)

 1915 Rexford Road,

 Charlotte, NC

 28211

 (Address of Principal Executive Offices)

 (Zip Code)

 Registrant's Telephone Number, Including Area Code: ( 704) 366-7000

 Not Applicable

 (Former Name or Former Address, if Changed Since Last Report)

 Check the appropriate box below if the Form 8-K
 filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12
 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement
 communications pursuant to Rule 14d-2(b)
 under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement
 communications pursuant to Rule 13e-4(c)
 under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading

 Symbol(s)

 Name of each exchange

 on which registered

 Common Stock, par value $0.40 per share

 NUE

 New York Stock Exchange

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
 of the Securities Exchange Act of 1934 (§ 240.12b-2
 of this chapter).
 Emerging growth company
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Item 1.05.

 Material Cybersecurity Incidents.

 Nucor Corporation (the "Company") recently identified a cybersecurity incident involving unauthorized third party access to certain information technology systems used by the Company. Upon detecting the incident, the Company began promptly taking steps to contain and respond to the incident, including activating its incident response plan, proactively taking potentially affected systems offline and implementing other containment, remediation, or recovery measures. The Company is actively investigating the incident with the assistance of leading external cybersecurity experts and has notified federal law enforcement authorities. As of the date of this filing and in an abundance of caution, the Company temporarily and proactively halted certain production operations at various locations. However, the Company is currently in the process of restarting the affected operations.
 As the investigation of the incident is ongoing, the Company will continue to monitor the timing and materiality of the incident.
 Forward-Looking Statements

 Certain statements made in this report, or in other public filings, press releases, or other written or oral communications made by Nucor, which are not historical facts are forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. The words "anticipate," "believe," "expect," "intend," "project," "may," "will," "should," "could" and similar expressions are intended to identify those forward-looking statements. These forward-looking statements reflect the Company's best judgment based on current information, and, although we base these statements on circumstances that we believe to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance, and actual results may vary materially from the projected results and expectations discussed in this report. Factors that might cause the Company's actual results to differ materially from those anticipated in forward-looking statements include, but are not limited to: the Company's ongoing assessment of the impacts of the cybersecurity incident, including the Company's potential discovery of additional information related to the incident in connection with its investigation or otherwise; the Company's expectations regarding its ability to contain and remediate the cybersecurity incident; the impact of the cybersecurity incident on the Company's relationships with customers, employees, and governmental regulators; the legal, reputational, and financial risks resulting from the cybersecurity incident, including as may arise from any potential regulatory inquiries and/or litigation to which the Company may become subject in connection with the incident; remediation and other additional costs that may be incurred by the Company in connection with the investigation and remediation of the incident; and the risks discussed in "Item 1A. Risk Factors" of the Company's Annual Report on Form 10-K
 for the year ended December 31, 2024, as may be supplemented by "Item 1A. Risk Factors" in the Company's subsequent Quarterly Reports on Form 10-Q
 and in the Company's other periodic and current reports filed with the SEC.

 SIGNATURES

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 NUCOR CORPORATION

 Date: May 14, 2025

 By:

 /s/ Stephen D. Laxton

 Stephen D. Laxton

 Chief Financial Officer and Executive

 Vice President


10-K/A

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K/A

 (Amendment No. 2)

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended December 31, 2024

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to

 Commission file number 001-36697

 DBV Technologies S.A.

 (Exact name of registrant as specified in its charter)

 France

 Not applicable

 (State or other jurisdiction of

 incorporation organization)

 (I.R.S. Employer

 Identification No.)

 107 avenue de la R publique

 92320 Ch tillon France

 Not applicable

 (Address of principal executive offices)

 (ZipCode)

 Registrant's telephone number, including area code: + 33 1 55 42 78 78

 Securities registered pursuant to Section 12(b)of the Act:

 Title of each class

 Trading

 Symbol(s)

 Name of each exchange

 on which registered

 American Depository Shares, each representing five ordinary shares, nominal value 0.10 per share

 DBVT

 The Nasdaq Stock Market LLC

 Ordinary shares, nominal value 0.10 per share

 n/a

 The Nasdaq Stock Market LLC

 Securities registered pursuant to Section 12(g) of the Act: None

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company," and "emerging growth company" in Rule 12b-2
 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
 of the Act). Yes No
 The aggregate market value of the voting and non-voting
 common equity held by non-affiliates
 based on the closing price per American Depositary Share, or ADS, of the registrant's ADSs on The Nasdaq Global Select Market on June 30, 2024 (the last business day of the registrant's most recently completed second fiscal quarter) was $ 84.2 million.
 As of April 30, 2025, the registrant had 136,948,872 ordinary shares, nominal value 0.10 per share, outstanding.
 Auditor Firm PCAOB ID: 1756 Auditor name: Deloitte & Associ s Auditor location: Paris - La D fense, France
 Auditor Firm PCAOB ID: 1253 Auditor name: KPMG S.A. Auditor Location: Paris - La D fense, France

 EXPLANATORY NOTE

 This Amendment No. 2 to Form 10-K
 (this "Form 10-K/A")
 amends the Annual Report on Form 10-K
 of DBV Technologies S.A., a Delaware corporation ("DBV," "we," "us," the "registrant" or the "Company," including our subsidiaries, as applicable), for the year ended December 31, 2024 that we originally filed with the U.S. Securities and Exchange Commission (the "SEC") on April 11, 2025 (the "Original Filing"), as amended on April 28, 2025 by Amendment No. 1 (the "Amendment No. 1"). This Form 10-K/A
 is being filed for the purpose of amending the beneficial ownership table contained in Part III, Item 12 to update beneficial ownership information and footnotes for 5% shareholders that were inadvertently excluded or miscalculated by an immaterial amount due to unintentional error. This Form 10-K/A
 also includes an updated Description of Registered Securities, filed as Exhibit 4.5, to make immaterial updates to the disclosure in the Description of American Depositary Shares section. Accordingly, this Form 10-K/A
 consists only of the facing page, this explanatory note, Item 12, Item 15, the signature pages to Form 10-K
 and the applicable exhibits. Capitalized terms not otherwise defined in Part III of this Form 10-K/A
 shall have the same meanings assigned to those terms in Parts I and II of the Original Filing.
 As required by Rule 12b-15 under
 the Exchange Act, new certifications by the Company's principal executive officer and principal financial officer are filed herewith as exhibits to this Form 10-K/A
 pursuant to Rule 13a-14(a)
 or 15d-14(a)
 of the Exchange Act. As no financial statements have
been included in this Form 10-K/A
 and this Form 10-K/A
 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K,
 paragraphs 3, 4, and 5 of the certifications have been omitted. Additionally, because this Form 10-K/A
 does not include financial statements, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 Except as set forth in this Form 10-K/A,
 this Form 10-K/A
 does not amend or otherwise update any other information in the Original Filing or the Amendment No. 1. Other than the information specifically amended and restated herein, this Form 10-K/A
 does not reflect events occurring after April 11, 2025, the date of the Original Filing, or modify or update those disclosures that may have been affected by subsequent events. Accordingly, this Form 10-K/A
 should be read in conjunction with the Original Filing and the Amendment No. 1 and with our filings with the SEC after the Original Filing.

 DBV Technologies S.A.
 Form 10-K/A

 Page

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 15. Exhibits and Financial Statement Schedules

 Exhibit Index

 Signatures

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
 The following table sets forth certain information with respect to the beneficial ownership of Ordinary Shares as of April 15, 2025 for:

 •

 each beneficial owner of more than 5% of our Ordinary Shares;

 •

 each of our named executive officers and directors; and

 •

 all of our executive officers and directors as a group.

 Beneficial ownership is determined in accordance with the rules and regulations of the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. In computing the number of Ordinary Shares beneficially owned by a person and the percentage ownership of that person, Ordinary Shares subject to options, warrants, or other rights held by such person that are currently exercisable or will become exercisable within 60 days of April 15, 2025, are considered outstanding. These Ordinary Shares, however, are not included in the computation of the percentage of ownership of any other person. Applicable percentage ownership is based on 136,948,872 Ordinary Shares outstanding plus 73,981,125 shares exercisable upon exercise of warrants and pre-funded warrants as of June 14, 2025.
 Unless otherwise indicated, the address for each of the shareholders listed in the table below is c/o DBV Technologies S.A., 107 avenue de la R publique 92320 Ch tillon, France.

 Number of
Shares
Beneficially
Owned

 Percentage
of Shares
Beneficially
Owned

 5% Shareholders

 Entities affiliated with Baker Bros. Advisors LP (1)

 23,468,163

 17.14

 %

 Entities affiliated with Bpifrance Participations S.A. (2)

 17,455,376

 12.16

 %

 Entities affiliated with Suvretta (3)

 15,176,304

 9.99

 %

 Entities affiliated with Vivo Opportunity Fund (4)

 14,614,449

 9.99

 %

 Entities affiliated with MPM BioImpact LLC (5)

 14,614,449

 9.99

 %

 Adage Capital Partners, L.P. (6)

 14,614,449

 9.99

 %

 Janus (7)

 14,614,449

 9.99

 %

 Octagon Opportunities Fund II LP. (8)

 13,997,797

 9.60

 %

 Entities affiliated with VR Advisor, LLC (9)

 9,654,655

 7.03

 %

 Citadel CEMF Investments Ltd. (10)

 9,158,677

 6.41

 %

 Named Executive Officers, Directors and Director Nominees

 Daniel Tass (11)

 1,361,693

 *

 Virginie Boucinha(12)

 34,500

 *

 Pharis Mohideen (13)

 441,533

 *

 Michel de Rosen (14)

 39,407

 *

 Ma lys Ferr re

 —

 —

 Michael J. Goller (15)

 21,500

 Daniele Guyot-Caparros

 —

 —

 Timothy E. Morris (16)

 18,837

 *

 Adora Ndu (17)

 8,662

 *

 Julie O'Neill (18)

 16,000

 *

 Ravi M. Rao (19)

 6,837

 *

 Daniel B. Soland (20)

 48,337

 *

 All current directors and current executive officers as a group (12 persons) (21)

 1,997,306

 1.44

 %

 *

 Represents beneficial ownership of less than 1% of our outstanding Ordinary Shares.

 (1)

 Based in part on information provided in the Schedule 13D/A filed by Baker Bros. Advisors LP on March 27, 2025 and other information provided to the Issuer. Consists of (a) 2,185,234 ordinary shares (including 120,036 ADSs representing 600,180 ordinary shares) held by 667, L.P. ("667") and (b) 21,282,929 ordinary shares (including 1,341,389 ADSs representing 6,706,945 ordinary shares) held by Baker Brothers Life Sciences, L.P ("Baker Life Sciences" and together with 667, the "Baker Funds"). In addition, (a) 667 has (i) 1,383,352 pre-funded warrants exercisable into 1,383,352 ordinary shares, (ii) 2,299,656 First Pre-Funded Warrants exercisable into 2,299,656 First PFW Shares, and (iii) 2,299,656 BS Warrants exercisable into 2,299,656 Second Pre-Funded Warrants, that are exercisable into 4,024,398 Second PFW Shares and (b) Baker Life Sciences has (i) 11,732,979 pre-funded warrants exercisable into 11,732,979 ordinary shares, (ii) 25,005,240 First Pre-Funded Warrants exercisable into 25,005,240 First PFW Shares, and (iii) 25,005,240 BS Warrants exercisable into 25,005,240 Second Pre-Funded Warrants, that are exercisable into 43,759,170 Second PFW Shares (together, the "Baker Warrants"). The Baker Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting no shares issuable upon exercise of the Baker Warrants. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Baker Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Baker Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Baker Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Baker Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Baker Funds except to the extent of their pecuniary interest therein. Michael Goller, a full-time employee of the Adviser currently serves on DBV's Board of directors as a representative of the Baker Funds. The policy of the Baker Funds and the Adviser does not permit full-time employees of the Adviser to receive compensation for serving as directors of any issuer, and the Baker Funds are instead entitled to the pecuniary interest in the Baker Warrants. Michael Goller has no voting power, dispositive power or pecuniary interest in the Baker Warrants. Other than through their control of the Adviser, Felix J. Baker and Julian C. Baker have neither voting nor dispositive power and have no direct pecuniary interest in the Baker Warrants held by Michael Goller. The Baker Funds are instead entitled to the pecuniary interest in the Baker Warrants held by Michael Goller. The Adviser has voting and investment power over the Baker Warrants held by Michael Goller. The address for each of these entities is 860 Washington Street, 3rd Floor, New York, New York 10014.

 (2)

 Based in part, on information provided in Schedule 13D/A filed jointly by (i) Bpifrance Participations S.A., a soci t anonyme incorporated under the laws of the Republic of France ("BpiP"), (ii) Innobio FPCI, a fonds professionnel de capital investissement ("Innobio"), (iii) Bpifrance Investissement S.A.S., a French management company (soci t de gestion) ("BpiI"), (iv) the Caisse des D p ts, a French special public entity ( tablissement sp cial) ("CDC"), (v) EPIC Bpifrance, a French public institution of industrial and commercial nature ("EPIC"), and (vi) Bpifrance S.A. ("BPI"), a soci t anonyme incorporated under the laws of the Republic of France, on April 7, 2025. Consists of (i) 10,672,462 ordinary shares held by BPIp, (ii) 6,556,781 ABSA Warrant Shares issuable upon exercise of 3,746,732 ABSA

Warrants held by BPIp, and (iii) 226,133 ordinary shares held by Innobio. BpiI may be deemed to be the beneficial owner of the 226,133 ordinary shares held by Innobio, through its management of Innobio. BPI may be deemed to be the beneficial owner of all of these securities, indirectly through its sole ownership of BPIp, which is the parent company of BpiI. CDC and EPIC Bpifrance may be deemed to be the beneficial owners of all of these securities indirectly through their joint ownership and control of BPI. The principal address for CDC is 56, rue de Lille, 75007 Paris, France. The principal address for Innobio, BpiI, EPIC Bpifrance and BPI is 27-31, avenue du G n ral Leclerc, 94710 Maisons-Alfort Cedex, France. The principal address for BPIp is 6/8 boulevard Haussmann, 75009 Paris, France.

 (3)

 Based in part, on information provided in Schedule 13G filed on April 11, 2025. Consists of (a) 185,020 ordinary shares held by Averill Master Fund, Ltd. ("Averill Master Fund"), (b) 25,201 ordinary shares held by Averill Madison Master Fund, Ltd. ("Averill Madison Fund" and, together with Averill Master Fund, the "Averill Funds"), (c) 18,157,252 First PFW Shares issuable upon the exercise of the 18,157,252 First Pre-Funded Warrants held by Averill Master Fund, (ii) 2,429,200 First PFW Shares issuable upon the exercise of the 2,429,200 First Pre-Funded Warrants held by Averill Madison Master Fund, (d) 31,775,191 Second PFW Shares issuable upon the exercise of the 18,157,252 Second Pre-Funded Warrants held by Averill Master Fund and (iv) 4,251,100 Second PFW Shares issuable upon the exercise of the 2,429,200 Second Pre-Funded Warrants held by Averill Madison Master Fund. The First Pre-Funded Warrants and Second Pre-Funded Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting an aggregate of 14,966,083 shares issuable upon exercise of the First Pre-Funded Warrants and Second Pre-Funded Warrants. Suvretta Capital Management, LLC is the investment manager of the Averill Funds. Aaron Cowen is a control person of Suvretta Capital Management, LLC and as such may be deemed to beneficially own these shares. Mr. Cowen disclaims beneficial ownership of all ordinary shares held by the Averill Funds, other than, to the extent of any pecuniary interest therein. The principal address of the Averill Funds, Suvretta Capital Management, LLC and Mr. Cowen is 540 Madison Avenue, 7th Floor, New York, NY 10022.

 (4)

 Based in part, on information provided in Schedule 13G filed jointly by Vivo Opportunity Fund Holdings, L.P, Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P and Vivo Opportunity Cayman, LLC on April 8, 2025. Consists of (i) 4,672,520 ordinary shares, (ii) 8,176,910 ABSA Warrant Shares issuable upon exercise of 4,672,520 ABSA Warrants, (iii) 2,730,560 First PFW Shares issuable upon exercise of 2,730,560 First Pre-Funded Warrants, and (iv) 4,778,480 Second PFW Shares issuable upon the exercise of the 2,730,560 Second Pre-Funded Warrants underlying the 2,730,560 BS Warrants held by Vivo Opportunity Fund Holdings, L.P. and (v) 600,012 Ordinary Shares, (v) 1,050,021 ABSA Warrant Shares issuable upon exercise of 600,012 ABSA Warrants, (vii) 350,640 First PFW Shares issuable upon exercise of 350,640 First Pre-Funded Warrants, and (viii) 613,620 Second PFW Shares issuable upon the exercise of the 350,640 Second Pre-Funded Warrants underlying the 350,640 BS Warrants, held by Vivo Opportunity Cayman Fund, L.P.. The Pre-Funded Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting an aggregate of 114,986 shares issuable upon exercise of the Pre-Funded Warrants held by Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC may be deemed to share voting, investment and dispositive power over the shares held by the Vivo Funds. The principal business address of the Vivo Funds, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC is 192 Lytton Avenue, Palo Alto, California 94301.

 (5)

 Based on information provided to the Issuer. Consists of (a) 1,835,344 ordinary shares held by BioImpact Equities Fund, LP ("BioImpact Equities Fund"), (b) 725,484 ordinary shares held by GTM Capital Healthcare Fund, L.P. ("GTM Fund"), (c) 1,252,216 ordinary shares held by MPM BioImpact Innovations Equities Master, LP ("MPM Innovations Fund"), (d) 495,712 ordinary shares held by BioImpact Equities Master Fund, LP ("BioImpact Master Fund"), (e) 773,796 ordinary shares held by Oncology Impact Fund 2, L.P. ("Oncology Impact Fund"), and (f) 189,980 ordinary shares held by New Technologies and Virology Fund, L.P. ("NTV Fund" and, together with BioImpact Equities Fund, GTM Fund, MPM Innovations Fund, BioImpact Master Fund and Oncology Impact Fund, the "MPM Funds"). In addition, (a) BioImpact Equities Fund has (i) 1,835,344 ABSA Warrants exercisable into 3,211,852 Warrant Shares, (ii) 3,518,816 First Pre-Funded Warrants exercisable into 3,518,816 First PFW Shares, and (iii) 3,518,816 BS Warrants exercisable into 3,518,816 Second Pre-Funded Warrants, that are exercisable into 6,157,928 Second PFW Shares, (b) GTM Fund has (i) 725,484 ABSA Warrants exercisable into 1,269,597 ABSA Warrant Shares, (ii) 1,390,936 First Pre-Funded Warrants exercisable into 1,390,936 First PFW Shares, and (iii) 1,390,936 BS Warrants exercisable into 1,390,936 Second Pre-Funded Warrants, that are exercisable into 2,434,138 Second PFW Shares, (c) MPM Innovations Fund has (i) 1,252,216 ABSA Warrants exercisable into 2,191,378 ABSA Warrant Shares, (ii) 2,400,816 First Pre-Funded Warrants exercisable into 2,400,816 First PFW Shares, and (iii) 2,400,816 BS Warrants exercisable into 2,400,816 Second Pre-Funded Warrants, that are exercisable into 4,201,428 Second PFW Shares, (d) BioImpact Master Fund has (i) 495,712 ABSA Warrants exercisable into 867,496 ABSA Warrant Shares, (ii) 950,408 First Pre-Funded Warrants exercisable into 950,408 First PFW Shares, and (iii) 950,408 BS Warrants exercisable into 950,408 Second Pre-Funded Warrants, that are exercisable into 1,663,214 Second PFW Shares, (e) Oncology Impact Fund has (i) 773,796 ABSA Warrants exercisable into 1,354,143 ABSA Warrant Shares, (ii) 1,483,564 First Pre-Funded Warrants exercisable into 1,483,564 First PFW Shares, and (iii) 1,483,564 BS Warrants exercisable into 1,483,564 Second Pre-Funded Warrants, that are exercisable into 2,596,237 Second PFW Shares, and (f) NTV Fund has (i) 189,980 ABSA Warrants exercisable into 332,465 ABSA Warrant Shares, (ii) 364,240 First Pre-Funded Warrants exercisable into 364,240 First PFW Shares, and (iii) 364,240 BS Warrants exercisable into 364,240 Second Pre-Funded Warrants, that are exercisable into 637,420 Second PFW Shares. The Pre-Funded Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting an aggregate of 114,986 shares issuable upon exercise of the First Pre-Funded Warrants and Second Pre-funded Warrants. MPM BioImpact LLC serves as the investment adviser to the MPM Funds. Christiana Bardon is a control person of the MPM Funds and as such may be deemed to beneficially own these shares. Ms. Bardon disclaims beneficial ownership of all ordinary shares held by the MPM Funds, other than, to the extent of any pecuniary interest therein. The principal address of the MPM Funds, MPM BioImpact LLC and Ms. Bardon is 399 Boylston Street, Suite 1100, Boston, MA 02116.

 (6)

 Based on information provided to the Issuer. Consists of (a) 5,272,532 ordinary shares, (b) 9,226,931 ABSA Warrant Shares issuable upon exercise of 5,272,532 ABSA Warrants, (c) 4,962,164 First PFW Shares issuable upon the exercise of 4,962,164 First Pre-Funded Warrants, (d) 8,683,787 Second PFW Shares issuable upon the exercise of the 4,962,164 Second Pre-Funded Warrants underlying the 4,962,164 BS Warrants held by Adage Capital Partners, L.P. ("Adage"). The Pre-Funded Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting an aggregate of 114,986 shares issuable upon exercise of the First Pre-Funded Warrants and Second Pre-funded Warrants. Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities

held by Adage Capital Partners, LP and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The principal address of Adage, Mr. Atchinson, Mr. Gross, Adage Capital Advisors, L.L.C., and Adage Capital Partners GP, L.L.C. is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

 (7)

 Based on information provided to the Issuer. Consists of (a) 4,666,192 ordinary shares held by Janus Henderson Biotech Innovation Master Fund Limited ("Janus Master Fund"), (b) 8,165,836 ABSA Warrant Shares held by Janus Master Fund issuable upon exercise of 4,666,192 ABSA Warrants, (c) 4,391,516 First Pre-Funded Warrants held by Janus Master Fund exercisable into 4,391,516 First PFW Shares, (d) 4,391,516 BS Warrants held by Janus Master Fund exercisable into 4,391,516 Second Pre-Funded Warrants, that are exercisable into 7,685,153 Second PFW Shares, (e) 606,340 ordinary shares held by Janus Henderson Biotech Innovation Master Fund II Limited ("Janus Master Fund II" and, together with Janus Master Fund, the "Janus Funds"), (f) 1,061,095 ABSA Warrant Shares held by Janus Master Fund II issuable upon exercise of 606,340 ABSA Warrants, (g) 570,648 First Pre-Funded Warrants held by Janus Master Fund II exercisable into 570,648 First PFW Shares, (h) 570,648 BS Warrants held by Janus Master Fund II exercisable into 570,648 Second Pre-Funded Warrants, that are exercisable into 998,634 Second PFW Shares. The Pre-Funded Warrants are subject to the Beneficial Ownership Limitation, and the amounts and percentages in the table give effect to the Beneficial Ownership Limitation, reflecting an aggregate of 114,986 shares issuable upon exercise of the First Pre-Funded Warrants and Second Pre-funded Warrants. The shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC ("Janus"), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Janus Funds and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of the Janus Funds. Under the terms of its management contract with the Janus Funds, Janus has overall responsibility for directing the investments of the Janus Funds in accordance with the Janus Funds' investment objective, policies and limitations. The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure of Janus whom makes decisions with respect to the disposition of the Resale Shares offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206. The portfolio managers for the Janus Funds are: Andrew Acker, Daniel S. Lyons and Agustin Mohedas.

 (8)

 Based on information provided to the Issuer. Consists of (a) 5,090,108 ordinary shares and (b) 8,907,689 ABSA Warrant Shares issuable upon exercise of 5,090,108 ABSA Warrants held by Octagon Private Opportunities Fund II LP ("Octagon Fund"). Octagon Capital Advisors LP ("Octagon Capital") serves as the investment manager of Octagon Fund. Ting Jia is the managing member of Octagon Capital. By virtue of these relationships each of Octagon Capital and Mr. Jia may be deemed to beneficially own the securities directly owned by Octagon Fund. The principal business address of each of the foregoing persons is 654 Madison Avenue, 21st Floor, New York, New York 10065.

 (9)

 Based on information provided to the Issuer. Consists of (i) 951,439 shares and 36,283 shares issuable upon the exercise of immediately exercisable Warrants held by Venrock Healthcare Capital Partners II, L.P., (ii) 385,717 shares and 14,709 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 2,093,431 shares and 79,833 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 209,422 shares and 7,986 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 5,659,991 shares and 215,844 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P.

 (10)

 Based in part, on information provided in Schedule 13G filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin on April 14, 2025. Consists of (i) 3,330,428 ordinary shares and (ii) 5,828,249 ABSA Warrant Shares issuable upon exercise of 3,330,428 ABSA Warrants held by Citadel CEMF Investments Ltd. Citadel Advisors LLC is the portfolio manager of Citadel CEMF Investments Ltd. CAH is the sole member of Citadel Advisors LLC. CGP is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr. Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition over the securities held by Citadel CEMF Investments Ltd. This disclosure is not and shall not be construed as an admission that Mr. Griffin or any of the Citadel-related entities listed above is the beneficial owner of any of our securities other than the securities actually owned by such person (if any). The address of Citadel CEMF Investments Ltd. is c/o Citadel Enterprise Americas LLC, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131.

 (11)

 Consists of 1,361,693 shares issuable upon the exercise of options that are exercisable within 60 days of April 15, 2025.

 (12)

 Consists of (a) 4,750 shares and (b) 29,750 shares issuable upon the exercise of options that are exercisable within 60 days of April 15, 2025.

 (13)

 Consists of (a) 25,833 shares and (b) 415,700 shares issuable upon the exercise of options that are exercisable within 60 days of April 15, 2025.

 (14)

 Consists of (a) 23,570 shares and (b) 15,837 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (15)

 Consists of 21,500 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law. Mr. Goller has neither voting nor dispositive power and has no direct pecuniary interest in these securities. He has entered into an agreement with Baker Bros. Advisors LP related to his beneficial ownership of our securities, as disclosed in a Schedule 13D/A filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker and Julian C. Baker on October 11, 2019.

 (16)

 Consists of (a) 12,000 shares and (b) 6,837 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (17)

 Consists of (a) 1,825 shares and (b) 6,837 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (18)

 Consists of 16,000 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (19)

 Consists of 6,837 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (20)

 Consists of (a) 20,000 shares and (b) 28,337 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025, subject to French law.

 (21)

 Consists of (a) 87,978 shares, (b) 1,807,143 shares issuable upon the exercise of options that are exercisable within 60 days of April 15, 2025, and (c) 102,185 shares issuable upon the exercise of warrants that are exercisable within 60 days of April 15, 2025.

 ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES
 (a) The following documents are filed as part of this report:
 1. Financial Statements. The financial statements included in Part II, Item 8 of the 2024 10-K are filed as part of this Amendment.
 2. Financial Statement Schedules. All required schedules are omitted because they are not applicable or the required information is shown in the financial statements or the accompanying notes to the financial statements.
 3. Exhibits. The exhibits filed as part of this Amendment are listed in Item 15(b).

 (b) Exhibits.
 The following exhibits are filed as part of this Amendment:

 Description

 Schedule/ Form

 File Number

 File Date

 3.1**

 By-laws (status) of the registrant (English translation)

 3.1

 4.1**

 Form of Deposit Agreement

 Form F-1/A

 4.1

 10/15/2014

 4.2**

 Form of Amendment No. 1 to Deposit Agreement

 Form F-6 POS

 333-266202

 (a)(ii)

 05/17/2024

 4.3**

 Form of Amendment No. 2 to Deposit Agreement

 Form F-6 POS

 333-266202

 (a)(i)

 11/12/2024

 4.4**

 Form of American Depositary Receipt

 Form F-1/A

 4.1

 10/15/2014

 4.5*

 Description of Registered Securities

 4.6**

 Registration Rights Agreement, dated as of March 23, 2018, between the registrant, 667, L.P. and Baker Brothers Life Sciences, L.P.

 Form 6-K

 4.1

 03/23/2018

 4.7**

 Registration Rights Agreement, dated as of June 8, 2022, between the registrant and the Investors named therein.

 Form 8-K

 10.2

 06/13/2022

 4.8**

 Securities Purchase Agreement, dated as of June 8, 2022, between the registrant and the Subscribers named therein.

 Form 8-K

 10.1

 06/13/2022

 10.1**

 Office Lease between the registrant and GENERALI VIE, dated March 3, 2025 (English translation)

 4.2

 04/29/2015

 10.2**

 Office Lease between the registrant and SCI DANTON MALAKOFF, dated October 2, 2023 (English translation)

 10.2

 10.3**

 Lease Agreement between DBV Technologies Inc. and SIG 106 LLC, dated March 28, 2022

 10.3

 10.4**

 Assignment, Development and Co-Ownership Agreement among the registrant, L'Assistance Publique-Hopitaux de Paris and Universit Paris Descartes, dated January 7, 2009 (English translation)

 10.2

 10.4**#

 Development Collaboration and License Agreement between the registrant and NESTEC S.A., dated May 27, 2016

 4.14

 03/22/2017

 10.5**#

 Amendment to Development Collaboration and License Agreement between the registrant and NESTEC S.A., dated July 12, 2018

 4.5

 04/01/2019

 10.6***

 Letter Agreement Terminating Development Collaboration and License Agreement between registrant and Soci t des Produits Nestl S.A. (f/k/a NESTEC S.A.), dated October 26, 2023

 10.7

 10.7**

 Form of Indemnification Agreement between the registrant and each of its executive officers and directors

 Form F-1/A

 10.3

 10/15/2014

 10.8**

 2013 and 2014 Share Option Plans (English translation)

 10.4

 10.9**

 2012, 2013 and 2014 Free Share Plans (English translation)

 10.5

 10.10**

 Summary of BSA

 10.6

 Description

 Schedule/ Form

 File Number

 File Date

 10.11**

 Summary of BSPCE

 10.7

 10.12**

 2015 Share Option Plan (English translation)

 4.10

 04/28/2016

 10.13**

 2015 Free Share Plans (English translation)

 4.11

 04/28/2016

 Description

 Schedule/ Form

 File Number

 File Date

 10.14**

 2016 Share Option Plan (English translation)

 4.12

 03/22/2017

 10.15**

 2016 Free Share Plan (English translation)

 4.13

 03/22/2017

 10.16**

 2017 Share Option Plan (English translation)

 4.14

 03/16/2018

 10.17**

 2017 Free Share Plan (English translation)

 4.15

 03/16/2018

 10.18**

 2018 Share Option Plan (English translation)

 4.17

 04/01/2019

 10.19**

 2018 Free Share Plan (English translation)

 4.18

 04/01/2019

 10.20**

 2019 Share Option Plan (English translation)

 4.19

 03/20/2020

 10.21**

 2019 Free Share Plan (English translation)

 4.20

 03/20/2020

 10.22**

 2020 Share Option Plan (English translation)

 10.21

 10.23**

 2020 Free Share Plan (English translation)

 10.22

 10.24**

 2021 Share Option Plan (English translation)

 10.22

 03/09/2022

 10.25**

 2021 Free Share Plan (English translation)

 10.23

 03/09/2022

 10.26**

 2022 Share Option Plan (English translation)

 10.24

 03/02/2023

 10.27**

 2022 Free Share Plan (English translation)

 10.25

 03/02/2023

 10.28**

 2023 Share Option Plan (English translation)

 S-8

 333-275662

 99.1

 11/20/2023

 10.29**

 2023 Free Share Plan (English translation)

 S-8

 333-275662

 99.2

 11/20/2023

 10.30**

 2024 Share Option Plan (English translation)

 S-8

 333-280657

 99.1

 07/30/2024

 10.31**

 2024 Free Share Plan (English translation)

 S-8

 333-280657

 99.2

 07/30/2024

 10.32**

 Executive Agreement, dated November 29, 2018, between the registration and Daniel Tass

 10.23

 10.33**

 First Amendment to the Executive Agreement of Daniel Tass, dated June 27, 2019, between the registrant and Daniel Tass

 10.24

 10.34**

 Executive Agreement, dated July 22, 2019, between the registrant and Pharis Mohideen

 10.25

 10.35**

 Letter Agreement, dated as of December 16, 2024, amending the Employment Agreement dated July 19, 2019, by and between registrant and Pharis Mohideen

 Form 8-K

 10.1

 12/16/2024

 10.39**

 Letter Agreement, dated November 1, 2023, between the registrant and Virginie Boucinha (English translation)

 10.37

 Description

 Schedule/ Form

 File Number

 File Date

 10.40**

 English Summary Translation of Letter Agreement dated as of December 16, 2024, amending the Employment Agreement dated November 6, 2023, by and between registrant and Virginie Boucinha

 Form 8-K

 001-36698

 10.2

 12/18/2024

 19.1**

 Securities Trading Policy

 19.1

 21.1**

 List of subsidiaries of the registrant

 21.1

 23.1**

 Consent of Deloitte & Associ s

 23.1

 23.2**

 Consent of KPMG S.A.

 23.2

 24.1**

 Power of Attorney (included on the signature page of this report).

 24.1

 31.1*

 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a- 14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 31.2*

 Certification of the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a- 14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 32.1***

 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 32.1

 97.1**

 Incentive Compensation Recoupment Policy, approved

 97.1

 03/01/2024

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 104*

 *

 Filed herewith.

 **

 Previously filed.

 ***

 Previously furnished and not deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 Indicates a management contract or any compensatory plan, contract or arrangement.

 #

 Confidential treatment has been granted from the Securities and Exchange Commission as to certain portions of this document.

 Signatures
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 Date: May 14, 2025

 DBV TECHNOLOGIES S.A.

 By:

 /s/ Daniel Tass

 Name:

 Daniel Tass

 Title:

 Chief Executive Officer


8-K/A

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

 FORM 8-K/A

 (Amendment No. 1)

 CURRENT REPORT

 Pursuant to Section 13 or 15(d)

 of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): May 13, 2025

 NUCOR CORPORATION

 (Exact name of Registrant as Specified in Its Charter)

 Delaware

 1-4119

 13-1860817

 (State or Other Jurisdiction

 of Incorporation)

 (Commission

 File Number)

 (IRS Employer

 Identification No.)

 1915 Rexford Road,

 Charlotte, NC

 28211

 (Address of Principal Executive Offices)

 (Zip Code)

 Registrant's Telephone Number, Including Area Code: ( 704) 366-7000

 Not Applicable

 (Former Name or Former Address, if Changed Since Last Report)

 Check the appropriate box below if the Form 8-K
 filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12
 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement
 communications pursuant to Rule 14d-2(b)
 under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement
 communications pursuant to Rule 13e-4(c)
 under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading

 Symbol(s)

 Name of each exchange

 on which registered

 Common Stock, par value $0.40 per share

 NUE

 New York Stock Exchange

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
 of the Securities Exchange Act of 1934 (§ 240.12b-2
 of this chapter).
 Emerging growth company
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Explanatory Note

 This Amendment No. 1 (this "Amendment") to the Current Report on Form 8-K
 filed by Nucor Corporation (the "Company") on May 14, 2025 (the "Original Form 8-K")
 provides supplemental information under Item 1.05 regarding the cybersecurity incident disclosed on the Original Form 8-K,
 and should be read in conjunction with the Original Form 8-K.

 Item 1.05.

 Material Cybersecurity Incidents.

 As disclosed in the Original Form 8-K,
 the Company recently experienced a cybersecurity incident affecting certain information technology systems used by the Company. The Company's investigation revealed that a threat actor illegally accessed the Company's information technology systems. The cybersecurity incident resulted in a temporary limitation of access to portions of the Company's information technology applications supporting some aspects of the Company's operations at some of the Company's facilities, and as noted in the Original Form 8-K,
 in an abundance of caution, the Company temporarily and proactively halted certain production operations at various locations. The Company's investigation also determined that the threat actor exfiltrated limited data from the Company's information technology systems. The Company is reviewing and evaluating the impacted data and will carry out any appropriate notifications to potentially affected parties and to regulatory agencies as required by applicable law.
 Upon detecting the unauthorized access, the Company immediately took steps to contain, assess, and remediate the cybersecurity incident, including activating its incident response plan, proactively taking potentially affected systems offline, restoring affected data from backup systems, and implementing other containment, remediation, and recovery measures. The Company also engaged leading external cybersecurity experts to assist with its investigation and recovery efforts and notified federal law enforcement authorities.
 Since the filing of the Original Form 8-K,
 the affected production operations, and access to necessary affected information technology applications, have been restored, and the Company believes that the threat actor no longer has access to the Company's information technology systems. As part of its remediation efforts, the Company worked with its outside cybersecurity experts to further reinforce its information technology systems and to prevent future unauthorized access.
 The cybersecurity incident has not had a material impact, and is not reasonably likely to have a material impact, on the Company's business operations, and has not had a material impact, and is not reasonably likely to have a material impact, on the Company's financial condition or results of operations.
 Forward-Looking Statements

 Certain statements made in this report, or in other public filings, press releases, or other written or oral communications made by Nucor, which are not historical facts are forward-looking statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. The words "anticipate," "believe," "expect," "intend," "project," "may," "will," "should," "could" and similar expressions are intended to identify those forward-looking statements. These forward-looking statements reflect the Company's best judgment based on current information, and, although we base these statements on circumstances that we believe to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance, and actual results may vary materially from the projected results and expectations discussed in this report. Factors that might cause the Company's actual results to differ materially from those anticipated in forward-looking statements include, but are not limited to: the Company's ongoing assessment of the impacts of the cybersecurity incident, including the Company's potential discovery of additional information related to the incident in connection with its investigation or otherwise; the Company's expectations regarding its ability to contain and remediate the cybersecurity incident; the impact of the cybersecurity incident on the Company's relationships with customers, employees, and governmental regulators; the legal, reputational, and financial risks resulting from the cybersecurity incident, including as may arise from any potential regulatory inquiries and/or litigation to which the Company may become subject in connection with the incident; remediation and other additional costs that may be incurred by the Company in connection with the investigation and remediation of the incident; and the risks discussed in "Item 1A. Risk Factors" of the Company's Annual Report on Form 10-K
 for the year ended December 31, 2024, as may be supplemented by "Item 1A. Risk Factors" in the Company's subsequent Quarterly Reports on Form 10-Q
 and in the Company's other periodic and current reports filed with the SEC.

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 NUCOR CORPORATION

 Date: June 20, 2025

 By:

 /s/ Stephen D. Laxton

 Stephen D. Laxton

 Chief Financial Officer and Executive
 Vice President


10-K/A

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K/A

 (Amendment No. 1)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the Fiscal Year Ended April 27, 2024

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the Transition Period From ___ to ___.

 Commission File Number: 001-38747

 Daktronics, Inc.

 (Exact Name of Registrant as Specified in Its Charter)

 Delaware

 46-0306862

 (State or Other Jurisdiction of

 Incorporation or Organization)

 (I.R.S. Employer

 Identification No.)

 201 Daktronics Drive

 Brookings, SD

 57006

 (Address of Principal Executive Offices)

 (Zip Code)

 ( 605) 692-0200

 (Registrant's telephone number, including area code)

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class

 Trading Symbol(s)

 Name of each exchange on which registered

 Common Stock, par value $0.00001 per share

 DAKT

 The Nasdaq Global Select Market

 Securities registered pursuant to Section 12(g) of the Act: None

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No
 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No
 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2
 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those errors corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
 of the Exchange Act). Yes No
 The aggregate market value of the registrant's common stock held by non-affiliates
 at October 26, 2024 (which is the last business day of the Registrant's most recently completed second quarter), computed by reference to the closing sales price of the Registrant's common stock on The Nasdaq Global Select Market on such date, was approximately $ 609,743,641. For purposes of determining this number, individual stockholders holding more than 10 percent of the Registrant's outstanding common stock are considered affiliates. This number is provided only for the purpose of this Annual Report on Form 10-K
 and does not represent an admission by either the Registrant or any such person as to the status of such person.
 The number of shares of the Registrant's common stock outstanding as of June 9, 2025 was 49,113,282.

 Auditor Name: Deloitte & Touche LLP

 Location: Minneapolis, Minnesota

 Auditor Firm ID: PCAOB No. 34

 EXPLANATORY NOTE
 On June 26, 2024, Daktronics, Inc. (the " Company

") filed its Annual Report on Form 10-K
 for the fiscal year ended April 27, 2024 (the "
 Original Form 10-K

 "
). This Amendment No. 1 (the "
 Amendment

 "
) is being filed solely to replace the consent of Deloitte & Touche LLP (the " Consent

") previously filed as Exhibit 23.1, Consent of Independent Registered Public Accounting Firm, to the Original Form 10-K.
 The Company possessed a correct, manually signed copy of the Consent when the Original Form 10-K
 was filed with the Securities and Exchange Commission (the " SEC

"), but due to an administrative error, an incorrect version of the Consent was inadvertently included in the Original Form 10-K.

 This Amendment includes Item 15 of Part IV of the Original Form 10-K
 that includes: (i) the corrected Consent; and (ii) as required by Rule 12b-15
 under the Securities Exchange Act of 1934, as amended (the " Exchange Act

"), new certifications by the Company's principal executive officer and principal financial officer pursuant to Rule 13a-14(a)
 or 15d-14(a)
 of the Exchange Act (collectively, the " Section

 Certifications

"). As no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 or 308 of Regulation S-K,
 paragraphs 3, 4, and 5 of the Section 302 Certifications have been omitted. Certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350) are not included herewith as no financial statements are being filed with this Amendment.
 This Amendment does not modify, amend, or update any of the financial statements or other information contained in the Original Form 10-K.
 Except for the foregoing amended information, the information disclosed in this Amendment does not reflect events occurring after the filing date of the Original Form 10-K.
 Therefore, this Amendment should be read together with other documents that the Company has filed with the SEC subsequent to the filing of the Original Form 10-K.
 Information in such reports and documents updates and supersedes certain information contained in the Original Form 10-K.

 PART IV.
 Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 (a)(3)

 Exhibits

 The following exhibits are filed as part of this Amendment. Certain of the following exhibits are incorporated by reference from prior filings. The form with which each exhibit was filed and the date of filing are as indicated below; the reports described below are filed as Commission File No. 001-38747 unless otherwise indicated.

 3.1

 Amended and Restated Articles of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 of the Quarterly Report on Form 10-Q/A (Amendment No. 1) of Daktronics, Inc. filed on December 21, 2018).

 3.2

 Amended and Restated Bylaws of the Company (Incorporated by reference to Exhibit 3.1 filed with our Current Report on Form 8-K filed on January 30, 2023).

 4.1

 Form of Stock Certificate Evidencing Common Stock, without par value, of the Company (Incorporated by reference to Exhibit 4.1 filed with our Amendment No. 1 to the Registration Statement on Form S-1 on January 12, 1994 as Commission File No. 33-72466).**

 4.2

 Rights Agreement dated as November 16, 2018 between Daktronics, Inc. and Equiniti Trust Company, as Rights Agent (Incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K of Daktronics, Inc. filed on November 16, 2018, Commission File No. 000-23246).

 4.3

 First Amendment to Rights Agreement dated as of November 19, 2021 between Daktronics, Inc. and Equiniti Trust Company, as Rights Agent (Incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K of Daktronics, Inc. filed on November 19, 2021).

 4.4

 Daktronics, Inc. 2007 Incentive Stock Plan (Incorporated by reference to Exhibit 10.1 filed with our Quarterly Report on Form 10-Q filed on August 20, 2007, Commission File No. 000-23246).*

 4.5

 Daktronics, Inc. 2015 Incentive Stock Plan ("2015 Plan") (Incorporated by reference to Exhibit A to the Company's Definitive Proxy Statement on Schedule 14A filed on July 14, 2015, Commission File No. 000-23246).*

 4.6

 Daktronics, Inc. 2020 Incentive Stock Plan ("2020 Plan") (Incorporated by reference to Exhibit A to the Company's Definitive Proxy Statement on Schedule 14A filed on July 16, 2020).*

 4.7

 Form of Restricted Stock Award Agreement under the 2020 Plan (Incorporated by reference to Exhibit 10.2 filed with our Current Report on Form 8-K filed on September 3, 2020).*

 4.8

 Form of Non-Qualified Stock Option Agreement Terms and Conditions under the 2020 Plan (Incorporated by reference to Exhibit 10.3 filed with our Current Report on Form 8-K filed on September 3, 2020).*

 4.9

 Form of Incentive Stock Option Terms and Conditions under the 2020 Plan (Incorporated by reference to Exhibit 10.4 filed with our Current Report on Form 8-K filed on September 3, 2020).*

 4.10

 Form of Restricted Stock Unit Terms and Conditions under the 2020 Plan (Incorporated by reference to Exhibit 10.5 filed with our Current Report on Form 8-K filed on September 3, 2020).*

 4.11

 Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. (Incorporated by reference to Exhibit 4.11 filed with our Annual Report on Form 10-K filed on July 12, 2023).)

 10.1

 Credit Agreement dated November 15, 2016 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on November 16, 2016, Commission File No. 000-23246).

 10.2

 Revolving Note dated November 15, 2016 issued by the Company to U.S. Bank National Association (Incorporated by reference to Exhibit 10.2 filed with our Current Report on Form 8-K filed on November 16, 2016, Commission File No. 000-23246).

 10.3

 Second Amendment to Credit Agreement dated as of November 15, 2019 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on November 15, 2019).

 10.4

 Third Amendment to Credit Agreement dated as of August 28, 2020 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.4 filed with our Current Report on Form 10-Q of Daktronics, Inc. filed on August 28, 2020).

 10.5

 Fourth Amendment to Credit Agreement dated as of March 11, 2021 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.5 filed with our Annual Report on Form 10-K filed on June 11, 2021).

 10.6

 Fifth Amendment to Credit Agreement dated as of April 29, 2022 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on April 29, 2022).

 10.7

 Amendment to Credit Agreement and Revolving Note dated as of August 16, 2022 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 files with our Current Report on Form 8-K filed on August 18, 2022).

 10.8

 Amendment to Credit Agreement and Revolving Note dated as of October 31, 2022 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on November 1, 2022).

 10.9

 Sixth Amendment to Credit Agreement dated as of December 9, 2022 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on December 13, 2022).

 10.10

 Seventh Amendment to Credit Agreement dated as of January 23, 2023 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K filed on January 25, 2023).

 10.11

 Security Agreement dated as of August 28, 2020 by and between the Company and U.S. Bank National Association (Incorporated by reference to Exhibit 10.5 filed with our Current Report on Form 10-Q of Daktronics, Inc. filed on August 28, 2020).

 10.12

 Cooperation Agreement dated July 23, 2022 by and between the Company and Prairieland Holdco, LLC (Incorporated by reference to Exhibit 10.1 filed with our Current Report on Form 8-K on July 27, 2022).

 10.13

 Standstill and Voting Agreement dated as of March 19, 2023 by and among Daktronics, Inc., Alta Fox Management, LLC and Connor Haley (Incorporated by reference to Exhibit 10.1 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on March 20, 2023).

 10.14

 Credit Agreement dated as of May 11, 2023 by and among Daktronics, Inc. and the other Borrowers; the other Loan Parties to the Credit Agreement; the Lenders party to the Credit Agreement; and JPMorgan Chase Bank, N.A., in its capacity as administrative agent for the Lenders (Incorporated by reference to Exhibit 10.1 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.15

 Pledge and Security Agreement dated as of May 11, 2023 by and among Daktronics, Inc., Daktronics Installation, Inc., and JPMorgan Chase Bank, N.A. (Incorporated by reference to Exhibit 10.2 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.16

 Securities Purchase Agreement dated as of May 11, 2023 by and between Daktronics, Inc. and Alta Fox Opportunities Fund, LP (Incorporated by reference to Exhibit 10.3 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.17

 Senior Secured Convertible Note dated as of May 11, 2023 issued by Daktronics, Inc. to Alta Fox Opportunities Fund, LP (Incorporated by reference to Exhibit 10.4 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.18

 Pledge and Security Agreement dated as of May 11, 2023 by and among Daktronics, Inc., Daktronics Installation, Inc., and Alta Fox Opportunities Fund, LP (Incorporated by reference to Exhibit 10.5 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.19

 Registration Rights Agreement dated as of May 11, 2023 by and between Daktronics, Inc. and Alta Fox Opportunities Fund, LP (Incorporated by reference to Exhibit 10.6 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 10.20

 Intercreditor Agreement dated as of May 11, 2023 by and among Daktronics, Inc., JPMorgan Chase Bank, N.A., and Alta Fox Opportunities Fund, LP (Incorporated by reference to Exhibit 10.7 filed with the Current Report on Form 8-K of Daktronics, Inc. filed on May 12, 2023).

 Daktronics, Inc. Stock Trading Policy for All Employees and Directors. (1)

 21.1

 Subsidiaries of the Company. (1)

 23.1

 Consent of Deloitte & Touche LLP. (2)

 Power of Attorney. (1)

 31.1

 Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (2)

 31.2

 Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (2)

 32.1

 Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350). ( 1)

 32.2

 Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350). (1)

 Daktronics, Inc. Clawback Policy. (1)

 (1)

 Filed with the Original Form 10-K.

 (2)

 Filed herewith.

 *

 Indicates a management contract or compensatory plan or arrangement

 **

 Paper Filing

 ADFLOW, AJT Systems, All Sport, Daktronics, D, DakStats, Data Display, DataTime, Fuelight, Fuelink, Galaxy, GalaxyPro, Go Digital, Keyframe, Liveticker, Matside, OmniSport, ProAd, ProPixel, ProRail, ProStar, Sportsound, Statvision, Tuff Sport, Uniview, Vanguard, Venus, Visiconn, V-Tour, V-Link, and Web-Sync are trademarks of Daktronics, Inc. All other trademarks referenced are the intellectual property of their respective companies.

 SIGNATURES
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized, on June 20, 2025.

 DAKTRONICS, INC.

 By:

 /s/ Howard I. Atkins

 Howard I. Atkins

 Acting Chief Financial Officer

 (Principal Financial Officer)